Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.…
Verrica (VRCA) Q3 2026 Earnings Call Transcript
Verrica Pharmaceuticals (NASDAQ: VRCA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 76 employees.
The shares were at 2.740 USD on 20 November 2026, down 23.5% over 52 weeks. Its 52-week range is 2.730 USD to 9.821 USD, and it trades at the bottom of that range.
Its market capitalisation is 47.07M USD.
Verrica Pharmaceuticals reports return on equity of -72.3%, an operating margin of -175.7% and revenue down 51.8% year over year.
It holds more cash than debt, a net cash position of 2.76M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 10 March 2027.